JP6228922B2 - Hpvキメラ粒子 - Google Patents

Hpvキメラ粒子 Download PDF

Info

Publication number
JP6228922B2
JP6228922B2 JP2014544038A JP2014544038A JP6228922B2 JP 6228922 B2 JP6228922 B2 JP 6228922B2 JP 2014544038 A JP2014544038 A JP 2014544038A JP 2014544038 A JP2014544038 A JP 2014544038A JP 6228922 B2 JP6228922 B2 JP 6228922B2
Authority
JP
Japan
Prior art keywords
hpv
chimeric
vlp
seq
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014544038A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015500229A (ja
Inventor
エドワード・ピーター・リビッキ
インガ・イザベル・ヒッツェロス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Cape Town
Original Assignee
University of Cape Town
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Cape Town filed Critical University of Cape Town
Publication of JP2015500229A publication Critical patent/JP2015500229A/ja
Application granted granted Critical
Publication of JP6228922B2 publication Critical patent/JP6228922B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2014544038A 2011-12-01 2012-12-03 Hpvキメラ粒子 Expired - Fee Related JP6228922B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ZA2011/08841 2011-12-01
ZA201108841 2011-12-01
PCT/IB2012/056912 WO2013080187A1 (en) 2011-12-01 2012-12-03 Hpv chimaeric particle

Publications (2)

Publication Number Publication Date
JP2015500229A JP2015500229A (ja) 2015-01-05
JP6228922B2 true JP6228922B2 (ja) 2017-11-08

Family

ID=48534756

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014544038A Expired - Fee Related JP6228922B2 (ja) 2011-12-01 2012-12-03 Hpvキメラ粒子

Country Status (18)

Country Link
US (1) US9771397B2 (cg-RX-API-DMAC7.html)
EP (1) EP2785842A4 (cg-RX-API-DMAC7.html)
JP (1) JP6228922B2 (cg-RX-API-DMAC7.html)
KR (1) KR102013801B1 (cg-RX-API-DMAC7.html)
CN (1) CN103890177B (cg-RX-API-DMAC7.html)
AU (1) AU2012345443B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014012491A2 (cg-RX-API-DMAC7.html)
CA (1) CA2850293C (cg-RX-API-DMAC7.html)
HK (1) HK1198703A1 (cg-RX-API-DMAC7.html)
IL (1) IL232584B (cg-RX-API-DMAC7.html)
IN (1) IN2014DN03054A (cg-RX-API-DMAC7.html)
MX (1) MX355352B (cg-RX-API-DMAC7.html)
MY (1) MY184076A (cg-RX-API-DMAC7.html)
PH (1) PH12014500466A1 (cg-RX-API-DMAC7.html)
RU (1) RU2642287C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201401579UA (cg-RX-API-DMAC7.html)
WO (1) WO2013080187A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201403557B (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107252489A (zh) 2009-04-13 2017-10-17 法国健康和医学研究院 Hpv颗粒及其用途
WO2013119877A1 (en) 2012-02-07 2013-08-15 Aura Biosciences, Inc. Virion-derived nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells
WO2015042325A1 (en) 2013-09-18 2015-03-26 Aura Biosciences, Inc. Virus-like particle conjugates for diagnosis and treatment of tumors
CN104531741B (zh) * 2014-08-22 2016-08-24 天津康希诺生物技术有限公司 增强hpv抗原表位肽免疫原性的方法及类病毒颗粒、颗粒制备方法与应用
CN105801704B (zh) * 2014-12-31 2020-06-02 艾托金生物医药(苏州)有限公司 一种具有抗宫颈癌细胞活性的重组疫苗构建方法及应用
ES2999358T3 (en) 2015-08-18 2025-02-25 Rakuten Medical Inc Phthalocyanine dye conjugates and their storage
ES2992591T3 (en) 2015-08-18 2024-12-16 Rakuten Medical Inc Compositions, combinations and related methods for photoimmunotherapy
KR20180095511A (ko) 2015-10-30 2018-08-27 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 표적화된 암 요법
JP2020515629A (ja) 2017-04-04 2020-05-28 アヴィディア テクノロジーズ, インコーポレイテッド 免疫応答を誘導するためのペプチドベースのワクチン、それらの製造方法および使用
AU2018251788B2 (en) 2017-04-12 2025-04-10 Aura Biosciences, Inc. Targeted combination therapy
CN110891602A (zh) 2017-06-23 2020-03-17 帕多瓦有限责任公司 嵌合病毒样颗粒以及其作为免疫反应的抗原特异性重定向剂的用途
JP7641005B2 (ja) 2018-12-27 2025-03-06 ヴェリミューン インコーポレイテッド コンジュゲート型ウイルス様粒子および抗腫瘍免疫リダイレクタとしてのその使用
US12704501B2 (en) 2019-03-29 2026-08-11 Rakuten Medical, Inc. Methods for photoimmunotherapy and related biomarkers
WO2021013071A1 (zh) 2019-07-19 2021-01-28 神州细胞工程有限公司 人乳头瘤病毒多价免疫原性组合物
WO2021161179A1 (en) * 2020-02-10 2021-08-19 University Of Cape Town Plant produced bovine papillomavirus virus-like particles and pseudovirions
MX2023004465A (es) 2020-10-19 2023-06-19 Verimmune Inc Composiciones basadas en virus y métodos para redirigir respuestas inmunitarias preexistentes mediante su uso para el tratamiento del cáncer.
AU2023367780A1 (en) 2022-10-25 2025-03-27 Barinthus Biotherapeutics North America, Inc. Self-assembling nanoparticles
KR102821363B1 (ko) 2023-02-06 2025-06-13 영산대학교산학협력단 드론에 장착된 라이다 센서를 기초로 하는 수심 측량 시스템

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2264126T3 (es) * 1994-05-16 2006-12-16 MERCK & CO., INC. Vacunas contra el papilomavirus.
EP1105466B1 (en) 1998-08-14 2006-04-26 Merck & Co., Inc. Process for purifying human papillomavirus virus-like particles
US20020016372A1 (en) * 2000-07-31 2002-02-07 Allison Anthony Clifford Method for preventing and treating alzheimer's disease and brain damage associated with cardiov ascular disease and head injury
WO2003068804A2 (en) 2002-02-14 2003-08-21 Novavax, Inc. Novel insect cell line
US7407807B2 (en) * 2002-05-17 2008-08-05 University Of Cape Town Chimaeric human papillomavirus 16 I1 virus like particles and a method for preparing the particles
CN101166827B (zh) 2005-04-29 2013-09-04 开普敦大学 在植物中表达蛋白质
EP2416798B1 (en) * 2009-04-10 2017-09-20 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
US9566323B2 (en) 2009-06-19 2017-02-14 Eyegene Inc. Vaccine for cervical cancer
CA2768172A1 (en) * 2009-06-25 2010-12-29 Glaxosmithkline Biologicals S.A. Novel compositions
WO2011077371A1 (en) * 2009-12-22 2011-06-30 University Of Cape Town Method for enhancing the expression of hpv l1

Also Published As

Publication number Publication date
MY184076A (en) 2021-03-17
PH12014500466A1 (en) 2022-05-11
KR20140098061A (ko) 2014-08-07
US9771397B2 (en) 2017-09-26
ZA201403557B (en) 2020-10-28
HK1198703A1 (en) 2015-05-29
RU2014126587A (ru) 2016-01-27
MX355352B (es) 2018-04-17
EP2785842A1 (en) 2014-10-08
CN103890177A (zh) 2014-06-25
US20140377367A1 (en) 2014-12-25
EP2785842A4 (en) 2015-11-25
CA2850293A1 (en) 2013-06-06
IL232584B (en) 2018-10-31
IL232584A0 (en) 2014-06-30
CA2850293C (en) 2019-10-08
SG11201401579UA (en) 2014-07-30
BR112014012491A2 (pt) 2017-06-06
AU2012345443B2 (en) 2017-10-26
KR102013801B1 (ko) 2019-08-23
AU2012345443A1 (en) 2014-04-17
MX2014006520A (es) 2014-11-21
JP2015500229A (ja) 2015-01-05
IN2014DN03054A (cg-RX-API-DMAC7.html) 2015-05-15
RU2642287C2 (ru) 2018-01-24
WO2013080187A1 (en) 2013-06-06
NZ622595A (en) 2016-04-29
CN103890177B (zh) 2016-03-09

Similar Documents

Publication Publication Date Title
US9771397B2 (en) HPV chimaeric particle
Pineo et al. Immunogenic assessment of plant‐produced human papillomavirus type 16 L1/L2 chimaeras
Cerovska et al. Transient expression of Human papillomavirus type 16 L2 epitope fused to N-and C-terminus of coat protein of Potato virus X in plants
Paz De la Rosa et al. An HPV 16 L1-based chimeric human papilloma virus-like particles containing a string of epitopes produced in plants is able to elicit humoral and cytotoxic T-cell activity in mice
Kohl et al. Expression of HPV-11 L1 protein in transgenic Arabidopsis thaliana and Nicotiana tabacum
JP2009524699A (ja) 新規植物ウイルス粒子及びその不活性化の方法
Waheed et al. Plastid expression of a double‐pentameric vaccine candidate containing human papillomavirus‐16 L1 antigen fused with LTB as adjuvant: transplastomic plants show pleiotropic phenotypes
JP2017528137A (ja) 卓越した免疫学的特性を有する卓越したヒトパピローマウイルス抗原及びそれを含むワクチン
Muthamilselvan et al. Assembly of human papillomavirus 16 L1 protein in Nicotiana benthamiana chloroplasts into highly immunogenic virus-like particles
US20080213293A1 (en) Prevention and Treatment of Recurrent Respiratory Papillomatosis
WO2011077371A1 (en) Method for enhancing the expression of hpv l1
JP2023539356A (ja) 改変コロナウイルス構造タンパク質
CN104306995A (zh) 一种抗j亚群禽白血病病毒感染的表位疫苗及其制备方法和应用
Meshcheryakova et al. Cowpea mosaic virus chimeric particles bearing the ectodomain of matrix protein 2 (M2E) of the influenza A virus: production and characterization
NZ622595B2 (en) Hpv chimaeric particle
CZ20031859A3 (cs) Fúzní protein pro vakcinaci proti lidskému papillomaviru a způsob jeho produkce
EP1401493B1 (en) Subunit vaccines and processes for the production thereof
Pineo Plant production and immunogenic characterisation of Human papillomavirus chimaeric vaccines
US20250281594A1 (en) Truncated recombinant l1 protein of human papillomavirus
Castillo Esparza et al. Expression of the capsid protein of human papillomavirus in plants as an alternative for the production of vaccines.
WO2008115631A9 (en) Plant-produced compositions for treating papillomavirus infection and related methods
Šmídková et al. Transient expression of human papillomavirus type 16 virus-like particles in tobacco and tomato using a tobacco rattle virus expression vector
US20080160040A1 (en) Plant-produced compositions for treating papillomavirus infection and related methods
Hefferon Applications of plant-derived vaccines for developing countries
Chabeda Immunogenic assessment of plant-produced Human papillomavirus type 16 chimaeric L1: L2 virus-like particles and the production of an encapsidated therapeutic DNA vaccine candidate

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160719

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20161018

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161207

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20170530

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170828

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20170904

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20171003

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20171016

R150 Certificate of patent or registration of utility model

Ref document number: 6228922

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees